Please assess the completion status of the following clinical trial:

Trial Title: Scleroderma Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with limited or diffuse systemic scleroderma if they had evidence of active alveolitis on examination of bronchoalveolar-lavage (BAL) fluid (defined as neutrophilia of ≥3 percent, eosinophilia of ≥2 percent, or both)on thoracic high-resolution computed tomography (CT), any ground-glass opacity,~2. Onset of the first symptom of scleroderma other than Raynaud's phenomenon within the previous seven years,~3. An FVC between 45 and 85 percent of the predicted value~4. Grade 2 exertional dyspnea according to the baseline instrument of the Mahler Dyspnea Index (as measured with the use of the magnitude-of-task component).~Exclusion Criteria:~1. A single-breath carbon monoxide diffusing capacity (DlCO) that was less than 30 percent of the predicted value,~2. A history of smoking within the preceding six months, other clinically significant pulmonary abnormalities,~3. Clinically significant pulmonary hypertension requiring drug therapy.~4. Patients taking prednisone at a dose of more than 10 mg per day, those who had previously been treated for more than four weeks with oral cyclophosphamide or had received two or more intravenous doses,~5. Patients who recently received other potentially disease-modifying medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cylophosphamide (Type: EXPERIMENTAL): Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
- Placebo (Type: PLACEBO_COMPARATOR): Matching gel caps at a dose of 25 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).